Ambee Pharmaceuticals (DHA:AMBEEPHA) Debt-to-Equity: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:AMBEEPHA Ambee Pharmaceuticals Plc DHA:AMBEEPHA
18 GF Score
Price BDT788.90
View Full Analysis

What is Ambee Pharmaceuticals Debt-to-Equity?

Ambee Pharmaceuticals DHA:AMBEEPHA +1.54% 18 Debt-to-Equity is 0.00 as of . 20. GuruFocus rates DHA:AMBEEPHA with a GF Score™ of 18/100. Among 809 Drug Manufacturers companies, Ambee Pharmaceuticals ranks worse than 123609.27% on this metric.

Ambee Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Ambee Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Ambee Pharmaceuticals's Total Stockholders Equity for the quarter that ended in . 20 was BDT0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ambee Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

DHA:AMBEEPHA's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

Ambee Pharmaceuticals  (DHA:AMBEEPHA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ambee Pharmaceuticals Debt-to-Equity Related Terms

Ambee Pharmaceuticals Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Ambee Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ambee Pharmaceuticals Debt-to-Equity Chart

Ambee Pharmaceuticals Annual Data
Trend
Debt-to-Equity

Ambee Pharmaceuticals Semi-Annual Data
Debt-to-Equity

DHA:AMBEEPHA vs IMNPQ: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ambee Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ambee Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ambee Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ambee Pharmaceuticals's Debt-to-Equity falls into.


DHA:AMBEEPHA
18GF Score
Ambee Pharmaceuticals Plc DHA:AMBEEPHA
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ambee Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ambee Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=( + ) / N/A
=N/A

Ambee Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in . 20 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=( + ) /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a Debt-to-Equity of 0.00 as of . 20. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ambee Pharmaceuticals and its competitors. According to the industry distribution chart, Ambee Pharmaceuticals ranks #999999 out of 809 companies in the Drug Manufacturers industry.
Is Ambee Pharmaceuticals' Debt-to-Equity too high?
Ambee Pharmaceuticals' current Debt-to-Equity is 0.00. Based on the distribution chart, Ambee Pharmaceuticals ranks #999999 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ambee Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Ambee Pharmaceuticals' Debt-to-Equity compare to IMNPQ?
According to the Drug Manufacturers industry distribution chart, Ambee Pharmaceuticals ranks #999999 out of 809 companies for Debt-to-Equity. This places Ambee Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ambee Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambee Pharmaceuticals's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambee Pharmaceuticals stock overvalued right now?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Ambee Pharmaceuticals' overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ambee Pharmaceuticals (DHA:AMBEEPHA), the current Debt-to-Equity is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ambee Pharmaceuticals Business Description

Address 184/1 Tejgaon Industrial Area, Dhaka, BGD, 1208
Ambee Pharmaceuticals Plc formerly Ambee Pharmaceuticals Ltd manufactures a wide range of pharmaceutical products in Bangladesh. It is engaged in the business of manufacturing drugs and medicine and sales. Its products are sold in the form of tablets, capsules, liquids, gels, and injectables.
18GF Score

Get the complete analysis for DHA:AMBEEPHA

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT788.90
Price